|
【结 构 式】 
|
【分子编号】69331 【品名】(1R,2S,5S)-3-(2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 【CA登记号】 |
【 分 子 式 】C19H33N3O4 【 分 子 量 】367.489 【元素组成】C 62.10% H 9.05% N 11.43% O 17.41% |
合成路线1
该中间体在本合成路线中的序号：(I)Coupling of dipeptide derivative (I) with 3-amino-4-cyclobutyl-2-hydroxybutyramide hydrochloride (II) using EDC by means of NMM in DMF/CH2Cl2 gives the α-hydroxy amide (III) , which is finally oxidized under modified Swern conditions (DMSO, EDC and dichloroacetic acid in toluene) or by means of NaOCl and catalytic TEMPO in the presence of KBr and NaOAc/AcOH in MTBE/H2O .
In a modified procedure, treatment of acid (I) with N,N-dicyclohexylamine (IV) gives the corresponding salt (V), which is then coupled with compound (II) using EDC by means of either HOBt and NMM or DIEA in EtOAc, 2-hydroxypyridine in DMF/MTBE, DMAP in EtOAc/DMF, or 1,3,5-trimethoxy-2,4,6-triazine (TMT) and NMM in EtOAc/DMF to afford compound (III). Similarly, treatment of dimethylcyclohexylamine salt (V) with carbonyldiimidazole (CDI) in the presence of DIEA in DMF produces the corresponding acyl imidazolide, which, without isolation, is then coupled with compound (II) to furnish adduct (III) .
In a related strategy, boceprevir is obtained by coupling of dipeptide derivative (I) with 3-amino-4-cyclobutyl-2-oxobutyramide (VI) using EDC, HOBt and NMM in acetonitrile or via activation of (I) as the mixed anhydride with isobutyl chloroformate and NMM in EtOAc .
| 【1】 Njoroge, F.G., Venkatraman, S. (Schering Corp.). An inhibitor of heptatitis C. US 2005249702, WO 2005107745. |
| 【2】 Saksena, A., Nair, L.G., Lovey, R.G. et al. (Schering Corp.; Dendreon Corp.). Novel peptides as NS3-serine protease inhibitors of hepatitis C virus. CA 2473032, EP 1481000, JP 2005524628, US 2007032433, US 7244721, WO 2003062265. |
| 【3】 Lovey, R.G., Tamura, S.Y., Bennett, F. (Dendreon Corp.; Schering Corp.).Novel peptides as NS3-serine protease inhibitors of hepatitis C virus. CA 2410662, EP 1385870, JP 2004504404, JP 2009051860, US 2003216325, US 2004254117, US 7012066, WO 2002008244. |
| 【4】 Venkatraman, S., Bogen, S.L., Arasappan, A. et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl] amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S) carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006, 49(20): 6074-86. |
| 【5】 Wu, G.G., Xie, J., Rashatasakhon, P. (Schering Corp.). An oxidation process for the preparation of N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[N-[(tert-butylamino)carbonyl]-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide and related compounds. CA 2628738, EP 1966233, JP 2009515894, US 2007149459, US 7528263, WO 2008010831. |
| 【6】 Wong, G.S.K., Lee, H.-C., Vance, J.A., Tong, W., Iwama, T. (Schering Corp.). Process for preparing (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide. CA 2672620, WO 2008079216. |
| 【7】 Sudhakar, A., Dahanukar, V., Zavialov, I.A. et al. (Schering Corp.). Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo-[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl. CA 2526629, EP 1641754, JP 2006528133, US 2005059800, US 7326795, WO 2004113294. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 69331 | (1R,2S,5S)-3-(2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid | C19H33N3O4 | 详情 | 详情 | |
| (II) | 69332 | 3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride | C8H16N2O2.HCl | 详情 | 详情 | |
| (III) | 69333 | (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-(2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide | C27H47N5O5 | 详情 | 详情 | |
| (IV) | 69334 | N,N-Dimethylcyclohexylamine;Dimethylaminocyclohexane;Cyclohexyldimethylamine | 98-94-2 | C8H17N | 详情 | 详情 |
| (V) | 69335 | N,N-dimethylcyclohexanamine (1R,2S,5S)-3-(2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate | C19H33N3O4.C8H17N | 详情 | 详情 | |
| (VI) | 69336 | 3-amino-4-cyclobutyl-2-oxobutyramide | C8H14N2O2 | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(I)After protection of L-tert-leucine (VIIa) as the corresponding silyl ester (VIII) with TMSCl by means of HMDS or Et3N in refluxing CH2Cl2, condensation with tert-butyl isocyanate (IX), followed by acidic work up leads to urea derivative (X) . Subsequent coupling of carboxylic acid (X) with methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate HCl salt (XI) in the presence of EDC, HOBt and 2,6-lutidine in acetonitrile yields the dipeptide ester (XII) , which is finally hydrolyzed with LiOH in THF/H2O and optionally purified via its α-methylbenzylamine salt .
Alternatively, coupling of N-Boc-L-tert-leucine (VIIb) with the bicyclic amino ester (XI) in the presence of BOP reagent and NMM in CH2Cl2/DMF affords the N-Boc dipeptide (XIII), which is then deprotected by means of HCl in dioxane to give compound (XIV) . Finally, intermediate (XIV) is condensed with tert-butyl isocyanate (IX) in CH2Cl2 to give the urea compound (XII).
| 【2】 Saksena, A., Nair, L.G., Lovey, R.G. et al. (Schering Corp.; Dendreon Corp.). Novel peptides as NS3-serine protease inhibitors of hepatitis C virus. CA 2473032, EP 1481000, JP 2005524628, US 2007032433, US 7244721, WO 2003062265. |
| 【3】 Lovey, R.G., Tamura, S.Y., Bennett, F. (Dendreon Corp.; Schering Corp.).Novel peptides as NS3-serine protease inhibitors of hepatitis C virus. CA 2410662, EP 1385870, JP 2004504404, JP 2009051860, US 2003216325, US 2004254117, US 7012066, WO 2002008244. |
| 【4】 Venkatraman, S., Bogen, S.L., Arasappan, A. et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl] amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S) carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006, 49(20): 6074-86. |
| 【5】 Wu, G.G., Xie, J., Rashatasakhon, P. (Schering Corp.). An oxidation process for the preparation of N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[N-[(tert-butylamino)carbonyl]-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide and related compounds. CA 2628738, EP 1966233, JP 2009515894, US 2007149459, US 7528263, WO 2008010831. |
| 【6】 Wong, G.S.K., Lee, H.-C., Vance, J.A., Tong, W., Iwama, T. (Schering Corp.). Process for preparing (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide. CA 2672620, WO 2008079216. |
| 【7】 Sudhakar, A., Dahanukar, V., Zavialov, I.A. et al. (Schering Corp.). Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo-[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl. CA 2526629, EP 1641754, JP 2006528133, US 2005059800, US 7326795, WO 2004113294. |
| 【8】 Dener, J.M. (Virobay, Inc.). Process for the preparation of (S)-2-(3-tertbutylureido)-3,3-dimethylbutanoic acid. WO 2009039361. |
| 【1】 Njoroge, F.G., Venkatraman, S. (Schering Corp.). An inhibitor of heptatitis C. US 2005249702, WO 2005107745. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VIIa) | 69075 | (S)-2-amino-3,3-dimethylbutanoic acid;L-tert-leucine;L-2-Amino-3,3-dimethylbutanoic acid | 20859-02-3 | C6H13NO2 | 详情 | 详情 |
| (VIIb) | 22251 | (2S)-2-[(tert-butoxycarbonyl)amino]-3,3-dimethylbutyric acid;2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoic acid;N-(tert-butoxycarbonyl)-3-methyl-L-valine | 62965-35-9 | C11H21NO4 | 详情 | 详情 |
| (I) | 69331 | (1R,2S,5S)-3-(2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid | C19H33N3O4 | 详情 | 详情 | |
| (VIII) | 69337 | (S)-trimethylsilyl 2-amino-3,3-dimethylbutanoate | C9H21NO2Si | 详情 | 详情 | |
| (IX) | 16976 | tert-butylisocyanate; tert-butyl isocyanate; 2-isocyanato-2-methylpropane | 1609-86-5 | C5H9NO | 详情 | 详情 |
| (X) | 69338 | (S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoic acid | C11H22N2O3 | 详情 | 详情 | |
| (XI) | 69339 | methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate HCl salt | 565456-77-1 | C9H15NO2.HCl | 详情 | 详情 |
| (XII) | 69340 | methyl (1R,2S,5S)-3-(2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate | C20H35N3O4 | 详情 | 详情 | |
| (XIII) | 69341 | methyl (1R,2S,5S)-3-(2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate | C20H34N2O5 | 详情 | 详情 | |
| (XIV) | 69342 | methyl (1R,2S,5S)-3-(2-amino-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate hydrochloride | C15H26N2O3.HCl | 详情 | 详情 |